Welcome to Medincell. Here we are committed to creating better medicines for all.
Impacting Global Health with Purposeful Innovation
Latest news & events
Press Release: Consolidated Annual Financial Results
Press Release: Consolidated Annual Financial Results
Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation
Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
Medincell and iM4TB Join Forces to Fight Tuberculosis
Medincell and iM4TB Join Forces to Fight Tuberculosis
Improving health worldwide through new therapeutic options
Our talented team of international experts is committed to developing an innovative and diverse portfolio of breakthrough therapies.
Powered by proprietary cutting-edge long-acting injectable technology, we are redefining standards treatment efficiency and accessibility to enhance the quality of life for patients worldwide.
What is a long-acting injectable ?
In our commitment to advancing global health, we collaborate with leading pharmaceutical entities and foundations to introduce groundbreaking therapeutic solutions.
Key figures
1
FDA-approved best-in-class therapy based on our proprietary technology
2
potential first-in-class therapies in Phase 3 clinical trials
140
top-tier experts, all shareholders, steering our company's success
25
nationalities within our team, fostering a diverse and dynamic work environment
Products & R&D pipeline
At the core of our portfolio is a commitment to addressing critical medical challenges, aiming to profoundly impact not only patient lives but also society at large. Our innovative product candidates, rooted in our proprietary BEPO® long-acting injectable technology, are developed both in-house and in collaboration with leading international pharmaceutical firms and NGOs.
Products on market
Programs in clinical phase 3
mdc-TJK
In partnership with Teva Pharmaceuticals
Indication
Schizophrenia
Molecule
Olanzapine
Status
Clinical Phase 3
Technology
BEPO®
mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. It has the potential to be the first long-acting olanzapine with a favorable safety profile as other LAIs of olanzapine have an FDA black box warning for PDSS (Postinjection Delirium/Sedation Syndrome) that limits their use.
News related to the project
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®
New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI
New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI
Olanzapine LAI: No PDSS Observed After Completion of c.99% of the Targeted Injections for Submission
Olanzapine LAI: No PDSS Observed After Completion of c.99% of the Targeted Injections for Submission
Progress in the Development of the Products Portfolio and the R&D Pipeline
Progress in the Development of the Products Portfolio and the R&D Pipeline
Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine LAI and UZEDY® commercial progress
mdc-CWM
In partnership with AIC
Indication
Post-op pain
Molecule
Celecoxib
Status
Clinical Phase 3
Technology
BEPO®
Injected into the intra-articular space during Total Knee Replacement surgery and potentially active for as long as three months post-surgery, mdc-CWM is a sustained-release formulation of celecoxib for the reduction of postoperative pain and inflammation. The mdc-CWM project is a collaboration with Arthritis Innovation Corporation (AIC), based in Toronto, Canada, who finance and conduct the clinical development activities.
News related to the project
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
MedinCell: mdc-CWM clinical phase 3 will start in 2021
MedinCell: mdc-CWM clinical phase 3 will start in 2021
MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020
MedinCell announces that mdc-CWM progresses as planned
MedinCell announces that mdc-CWM progresses as planned
Join the team
Unleash your entrepreneurial spirit within a creative and innovative team of international experts dedicated to tackling global health challenges.
June 2025
Corporate presentation
Get in touch
Please use the form for any inquiries. We’ll get back to you promptly.
